Lidocaine infusions for refractory chronic migraine: a retrospective analysis

Ketamine for Refractory Chronic Migraine: an Observational Pilot Study and Metabolite Analysis

(2021) Eric S. Schwenk et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Beyond the Raskin Protocol: Ketamine, Lidocaine, and Other Therapies for Refractory Chronic Migraine

(2021) Jeffrey J. Mojica et al.   Current Pain and Headache Reports

Efficacy and safety of eptinezumab in patients with chronic migraine

(2020) Richard B. Lipton et al.   NEUROLOGY

European headache federation consensus on the definition of resistant and refractory migraine

(2020) Simona Sacco et al.   JOURNAL OF HEADACHE AND PAIN

Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

(2018) Messoud Ashina et al.   CEPHALALGIA

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

(2018)   CEPHALALGIA

The Use and Method of Action of Intravenous Lidocaine and Its Metabolite in Headache Disorders

(2018) Thomas Berk et al.   HEADACHE

Ketamine for Refractory Headache

(2018) Eric S. Schwenk et al.   REGIONAL ANESTHESIA AND PAIN MEDICINE

Fremanezumab for the Preventive Treatment of Chronic Migraine

(2017) Stephen D. Silberstein et al.   NEW ENGLAND JOURNAL OF MEDICINE

Defining the Pharmacologically Intractable Headache for Clinical Trials and Clinical Practice

(2010) Stephen D. Silberstein et al.   HEADACHE

Intravenous Lidocaine in the Treatment of Refractory Headache: A Retrospective Case Series

(2008) Michael Marmura et al.   HEADACHE